Higher expression of FAS, GPR29, HAVCR2, and NCAM1 in lung carcinoma patients exhibit longer survival time with hazard ratio and 95% confident interval of 0.79 (0.69-0.89), 0.80 (0.70-0.90), 0.71 (0.60-0.84), and 0.73 (0.62-0.86), respectively. This evidence concerns the gene FAS and lung carcinoma.